Syros Pharmaceuticals Inc (SYRS)

Jan 16, 2025

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com - Defense World

Jan 16, 2025

Jan 15, 2025

Analysts’ Revisions Show Improving Sentiment For Syros Pharmaceuticals Inc (NASDAQ: SYRS) - Stocks Register

Jan 15, 2025

Jan 09, 2025

Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listi - Defense World

Jan 09, 2025

Jan 08, 2025

Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com

Jan 08, 2025

Jan 08, 2025

Syros Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com South Africa

Jan 08, 2025

Jan 08, 2025

StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Jan 08, 2025

Jan 05, 2025

Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World

Jan 05, 2025

Dec 31, 2024

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Dec 31, 2024

Dec 30, 2024

November's phase III successes; Syros, Cassava tumble on misses - BioWorld Online

Dec 30, 2024

Dec 23, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World

Dec 23, 2024

Dec 15, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com India

Dec 15, 2024

Dec 11, 2024

JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN

Dec 11, 2024

Dec 06, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - The Eastern Progress Online

Dec 06, 2024

Dec 04, 2024

Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia

Dec 04, 2024

Dec 04, 2024

Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 - Investing.com

Dec 04, 2024

Nov 30, 2024

Syros Pharmaceuticals (LTS:0LC7) Enterprise Value : $8.13 Mil (As of Jan. 03, 2025) - GuruFocus.com

Nov 30, 2024

Nov 25, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World

Nov 25, 2024

Nov 24, 2024

SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com

Nov 24, 2024

Nov 23, 2024

Syros cut to neutral by H.C. Wainwright on failed drug study - MSN

Nov 23, 2024

Nov 22, 2024

Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India

Nov 22, 2024

Nov 21, 2024

Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia

Nov 21, 2024

Nov 21, 2024

Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia

Nov 21, 2024

Nov 21, 2024

Syros Pharmaceuticals chief legal officer sells $10,320 in stock - Investing.com India

Nov 21, 2024

Nov 20, 2024

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada

Nov 20, 2024

Nov 20, 2024

Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com

Nov 20, 2024

Nov 20, 2024

Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com

Nov 20, 2024

Nov 20, 2024

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN

Nov 20, 2024

Nov 20, 2024

Syros downgraded to Market Perform from Outperform at JMP Securities - MSN

Nov 20, 2024

Nov 20, 2024

Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN

Nov 20, 2024

Nov 20, 2024

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN

Nov 20, 2024

Nov 18, 2024

Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM

Nov 18, 2024

Nov 18, 2024

Syros Pharmaceuticals announces major company changes - Investing.com

Nov 18, 2024

Nov 18, 2024

Syros Pharmaceuticals announces major company changes By Investing.com - Investing.com UK

Nov 18, 2024

Nov 18, 2024

Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks

Nov 18, 2024

Nov 17, 2024

What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World

Nov 17, 2024

Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World

Nov 15, 2024

Nov 14, 2024

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance

Nov 14, 2024

Nov 14, 2024

JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia

Nov 14, 2024

Nov 13, 2024

Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada

Nov 13, 2024

Nov 13, 2024

No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online

Nov 13, 2024